Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Review proposal consultation

Stakeholder matrix (PDF 36 KB)

Review proposal paper (PDF 168 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: equality impact assessment - guidance development (PDF 167 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: final appraisal determination information

Macular oedema (retinal vein occlusion) - ranibizumab: final appraisal determination document (PDF 279 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 518 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: consultee and commentator comments on the ACD

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis (PDF 608 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: RNIB (PDF 18 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing (PDF 26 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists (PDF 108 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire (PDF 32 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wirral (PDF 21 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Allergan (PDF 86 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: BMJ group (PDF 73 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: expert comments on the  ACD

Macular oedema (retinal vein occlusion) - ranibizumab: Gibson (PDF 64 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Sivaprasad (PDF 20 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: comments on the ACD received from the public through the NICE website (PDF 63 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: ERG Critique of Novartis ACD Comments (PDF 316 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Specification (PDF 38 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Report (PDF 1.43 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: comments on the DSU Report

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments (PDF 166 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Macular Disease Society DSU comments (PDF 19 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: RNIB DSU comments (PDF 68 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing DSU comments (PDF 23 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists DSU comments (PDF 156 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire DSU comments (PDF 31 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Commissioning Support Appraisals Service DSU comments (PDF 216 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Allergan DSU comments (PDF 76 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Roche DSU comments (PDF 59 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Manufacturer Revised Patient Access Scheme submission (PDF 327 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: ERG Critique of Patient Access Scheme submission (PDF 184 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: appraisal consultation

Macular oedema (retinal vein occlusion) - ranibizumab: appraisal consultation document information

Macular oedema (retinal vein occlusion) - ranibizumab: evaluation report

Macular oedema (retinal vein occlusion) - ranibizumab: pre-meeting briefing (PDF 410 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Evidence Review Group report

Macular oedema (retinal vein occlusion) - ranibizumab: ERG report (PDF 2.79 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: ERG report erratum (PDF 375 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: additional ERG report (PDF 54 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Evidence Review Group - factual accuracy check (PDF 157 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer submission

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis submission (PDF 4.87 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis PAS submission (PDF 375 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: clarification

Macular oedema (retinal vein occlusion) - ranibizumab: NICE clarification letter (PDF 343 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer response to NICE clarification questions

Macular oedema (retinal vein occlusion) - ranibizumab: manufacturer response to the NICE clarification letter (PDF 1.23 MB)

Macular oedema (retinal vein occlusion) - ranibizumab: report (PDF 975 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: patient group, professional group and NHS organisation submission statements

Macular oedema (retinal vein occlusion) - ranibizumab: Royal National Institute of Blind People (RNIB)

Macular oedema (retinal vein occlusion) - ranibizumab: organisation statement (PDF 101 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study A (PDF 34 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study B (PDF 6.4 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study C (PDF 34 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study D (PDF 9 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: case study E (PDF 10 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing (PDF 140 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists (RCOPHTH) (PDF 125 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wirral (PDF 66 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: expert written personal statements

Macular oedema (retinal vein occlusion) - ranibizumab: Gibson (PDF 30 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Keeley (PDF 24 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Pearce (PDF 169 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Sivaprasad (PDF 119 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: Winyard (PDF 19 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: final scope (PDF 60 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: final matrix (PDF 49 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: equality impact assement - scoping (PDF 27 KB)

Macular oedema (retinal vein occlusion) - ranibizumab: draft scope for rescope consultation (PDF 56 KB)

Appendix C: provisional matrix (pre-referral) (PDF 30 KB)

Appendix B: draft scope for consultation (pre-referral) (PDF 34 KB)

Appendix C: provisional matrix (pre-referral) (PDF 30 KB)